333 related articles for article (PubMed ID: 17960171)
1. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples.
Shih LY; Liang DC; Huang CF; Chang YT; Lai CL; Lin TH; Yang CP; Hung IJ; Liu HC; Jaing TH; Wang LY; Yeh TC
Leukemia; 2008 Feb; 22(2):303-7. PubMed ID: 17960171
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
[TBL] [Abstract][Full Text] [Related]
3. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
Goemans BF; Zwaan CM; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen AH; Hählen K; Reinhardt D; Creutzig U; Kaspers GJ; Heinrich MC
Leukemia; 2005 Sep; 19(9):1536-42. PubMed ID: 16015387
[TBL] [Abstract][Full Text] [Related]
4. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).
Boissel N; Leroy H; Brethon B; Philippe N; de Botton S; Auvrignon A; Raffoux E; Leblanc T; Thomas X; Hermine O; Quesnel B; Baruchel A; Leverger G; Dombret H; Preudhomme C; ;
Leukemia; 2006 Jun; 20(6):965-70. PubMed ID: 16598313
[TBL] [Abstract][Full Text] [Related]
5. AML patients with CEBPalpha mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples.
Shih LY; Liang DC; Huang CF; Wu JH; Lin TL; Wang PN; Dunn P; Kuo MC; Tang TC
Leukemia; 2006 Apr; 20(4):604-9. PubMed ID: 16453003
[TBL] [Abstract][Full Text] [Related]
6. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
[TBL] [Abstract][Full Text] [Related]
7. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).
Nanri T; Matsuno N; Kawakita T; Suzushima H; Kawano F; Mitsuya H; Asou N
Leukemia; 2005 Aug; 19(8):1361-6. PubMed ID: 15902284
[TBL] [Abstract][Full Text] [Related]
8. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
9. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.
Christiansen DH; Andersen MK; Desta F; Pedersen-Bjergaard J
Leukemia; 2005 Dec; 19(12):2232-40. PubMed ID: 16281072
[TBL] [Abstract][Full Text] [Related]
10. FLT3-TKD mutation in childhood acute myeloid leukemia.
Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Wang LY; Chang WH
Leukemia; 2003 May; 17(5):883-6. PubMed ID: 12750701
[TBL] [Abstract][Full Text] [Related]
11. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia.
Park SH; Chi HS; Min SK; Park BG; Jang S; Park CJ
Leuk Res; 2011 Oct; 35(10):1376-83. PubMed ID: 21715005
[TBL] [Abstract][Full Text] [Related]
13. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657.
Goemans BF; Zwaan CM; Cloos J; de Lange D; Loonen AH; Reinhardt D; Hählen K; Gibson BE; Creutzig U; Kaspers GJ
Leuk Res; 2010 Oct; 34(10):1302-7. PubMed ID: 20435347
[TBL] [Abstract][Full Text] [Related]
14. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication.
Beghini A; Ripamonti CB; Cairoli R; Cazzaniga G; Colapietro P; Elice F; Nadali G; Grillo G; Haas OA; Biondi A; Morra E; Larizza L
Haematologica; 2004 Aug; 89(8):920-5. PubMed ID: 15339674
[TBL] [Abstract][Full Text] [Related]
15. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
[TBL] [Abstract][Full Text] [Related]
17. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
Sritana N; Auewarakul CU
Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
[TBL] [Abstract][Full Text] [Related]
19. KIT mutations confer a distinct gene expression signature in core binding factor leukaemia.
Lück SC; Russ AC; Du J; Gaidzik V; Schlenk RF; Pollack JR; Döhner K; Döhner H; Bullinger L
Br J Haematol; 2010 Mar; 148(6):925-37. PubMed ID: 20064158
[TBL] [Abstract][Full Text] [Related]
20. KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.
Chen X; Dou H; Wang X; Huang Y; Lu L; Bin J; Su Y; Zou L; Yu J; Bao L
Leuk Lymphoma; 2018 Apr; 59(4):829-836. PubMed ID: 28792268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
